ClinicalTrials.gg
CompletedNCT07944937Updated Nov 18, 2026

Virtual Reality-Assisted Distraction During Repeated Venipuncture

An interventional study of Virtual Reality-Assisted Distraction in Procedural Pain and Procedure-Related Anxiety, sponsored by Aydin Adnan Menderes University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aydin Adnan Menderes University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Mar 2022, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 80 studies in Pain, Procedural with a site in Turkey — 14 open to participants now, 14 under way, none of them phase 3. Pain, Procedural · Turkey.

Enrollment
69th of 78
60 · median 100
Started
2022
with 5 others
No phase
76 of 80
13 open now
Registered
80th of 80
by date
Lead sponsor
2 of 80
Aydin Adnan Menderes University

Among the 80 studies in Pain, Procedural with a site in Turkey, this one is the 69th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2022, is one of 76 with no phase, and was the 80th registered.

Pain, Procedural

245 studies on the registry are indexed under Pain, Procedural; 66 are open to participants now.

Browse Pain, Procedural studies →

Open to participants now

14 of the 80 studies in Pain, Procedural with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 30 Pain, Procedural studies recruiting now, 13 (43%) set no upper age limit and 15 (50%) stop at 75 or younger; 14 take children under 18; 6 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pain, Procedural with a site in Turkey, or all of them as a file.
02

Study summary

This study evaluated the effects of virtual reality (VR)-assisted distraction on procedural pain, state anxiety, and physiological responses during repeated venipuncture in adults undergoing oral glucose tolerance testing. The single-center, nonrandomized controlled study was conducted between March and June 2022. Participants were assigned according to their weekday of attendance to either a VR intervention group or a routine-care control group. Venous blood sampling was performed at 0, 30, and 60 minutes. Baseline assessments were obtained after the 30-minute venipuncture, and outcome assessments were repeated after the 60-minute venipuncture. During the final blood draw, participants in the intervention group viewed an immersive underwater environment through a VR headset, whereas controls received routine care. Outcomes included procedural pain intensity, state anxiety, pulse rate, blood pressure, respiratory rate, and body temperature. Of 66 allocated participants, 60 were included in the final analyses.

Read the detailed description

Venipuncture is a commonly performed clinical procedure that may cause pain, anxiety, and physiological stress responses. These responses may be particularly relevant when patients undergo repeated blood sampling within a short period, as required during an oral glucose tolerance test (OGTT). Virtual reality (VR)-assisted distraction is a nonpharmacological approach that may reduce attention to procedure-related stimuli by providing an immersive visual experience.

This study was designed to investigate the use of VR-assisted distraction during repeated venipuncture in adults undergoing an OGTT. The clinical protocol involved three consecutive blood-sampling procedures at 0, 30, and 60 minutes. The initial procedure was performed as part of routine care without research-related assessments. Following the second procedure, pain intensity, state anxiety, and physiological parameters were assessed to establish baseline measurements.

During the final venipuncture, the intervention group received VR-assisted distraction through a headset displaying a silent, animated underwater environment, while the control group continued to receive routine care. The VR intervention was initiated immediately before needle insertion and continued until completion of the procedure, lasting approximately one minute. Outcome measurements were repeated after the final venipuncture.

The study was conducted in a routine outpatient clinical setting to evaluate the potential applicability of brief VR-assisted distraction during repeated blood sampling. By assessing both patient-reported outcomes and physiological responses, the study sought to provide a multidimensional evaluation of this nonpharmacological intervention.

03

Conditions studied

  • Procedural Pain
  • Procedure-Related Anxiety

Keywords

  • Virtual Reality
  • Distraction
  • Repeated Venipuncture
  • Procedural Pain
  • State Anxiety
  • Oral Glucose Tolerance Test
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20-45 years.
  • Scheduled to undergo an oral glucose tolerance test (OGTT) requiring repeated venous blood sampling.
  • Receiving outpatient care.
  • Willing to participate in the study and providing written .

Exclusion criteria

Exclusion Criteria:

  • Hospitalized patients.
  • Individuals unable to read and write.
  • Individuals with a diagnosed psychiatric disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Virtual Reality-Assisted Distraction

    Participants received VR-assisted distraction during the 60-minute venipuncture of an oral glucose tolerance test. An immersive, silent underwater animation was presented through a VR headset immediately before and throughout venipuncture. Exposure lasted approximately one minute.

    Device: Virtual Reality-Assisted Distraction

  • No intervention
    Routine Care

    Participants underwent venipuncture at the corresponding time point under routine clinical conditions, without VR-assisted distraction or an additional distraction intervention.

Interventions

  • DeviceVirtual Reality-Assisted Distraction

    Virtual reality (VR)-assisted distraction was delivered using a Fiit VR headset (approximately 250-300 g) with a cushioned facial interface, biconvex lenses, and adjustable lens spacing. The immersive visual content consisted of a silent, animated underwater environment featuring moving fish and aquatic vegetation. The VR headset was fitted, and the animation was initiated immediately before the venipuncture performed at the 60-minute time point of the oral glucose tolerance test. Participants viewed the virtual environment continuously throughout venipuncture, and the headset was removed immediately after the procedure. Although the complete animation lasted approximately 10-15 minutes, actual VR exposure was limited to the duration of venipuncture, averaging approximately one minute. No VR intervention was administered during the preceding blood-sampling procedures at 0 and 30 minutes.

06

What researchers measure

Primary outcomes

  1. Procedural Pain Intensity Measured by the Numeric Rating Scale (NRS)

    Procedural pain intensity was assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (unbearable pain). Higher scores indicate greater pain intensity. Participants verbally rated the pain experienced during venipuncture. The outcome was the change in NRS score between the assessments following the 30-minute and 60-minute venipuncture procedures (60-minute score minus 30-minute score).

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

  2. State Anxiety Measured by the State-Trait Anxiety Inventory-State Form (STAI-S)

    State anxiety was evaluated using the Turkish version of the STAI-S, originally developed by Spielberger and colleagues and adapted for Turkish populations by Öner and Le Compte (Spielberger, 1983; Öner \& Le Compte, 1998). The instrument comprises 20 self-report items assessing transient anxiety experienced under specific circumstances. Ten positively worded items require reverse scoring. Total scores range from 20 to 80, with higher scores indicating greater state anxiety. Internal consistency coefficients of .83-.92 have been reported for the Turkish version.Assessments were performed following separate venipuncture procedures at 30 minutes (baseline, without VR in either group) and 60 minutes (VR intervention versus routine care). Between-group comparisons of post-procedure STAI-S scores were adjusted for baseline scores.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

Secondary outcomes

  1. Pulse Rate (Beats per Minute)

    Pulse rate was measured in beats per minute following venipuncture. Measurements were obtained at the 30-minute baseline assessment and repeated after the 60-minute venipuncture. Lower values indicate a lower heart rate.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

  2. Systolic Blood Pressure (mmHg)

    Systolic blood pressure was measured in millimeters of mercury (mmHg) following venipuncture. Measurements were obtained at 30 minutes under routine care in both groups and repeated at 60 minutes following VR-assisted distraction or routine care.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

  3. Diastolic Blood Pressure (mmHg)

    Diastolic blood pressure was measured in millimeters of mercury (mmHg) after venipuncture. Measurements were recorded at the 30-minute baseline assessment and repeated after the 60-minute procedure in both study groups.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

  4. Respiratory Rate (Breaths per Minute)

    Respiratory rate was measured as the number of breaths per minute following venipuncture. Assessments were performed after the 30-minute and 60-minute venipuncture procedures to evaluate respiratory responses in the VR-assisted distraction and routine-care groups.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

  5. Body Temperature (°C)

    Body temperature was measured in degrees Celsius (°C) following venipuncture. Measurements were recorded at 30 minutes before the VR intervention and repeated after the 60-minute venipuncture in both groups.

    Time frame: Immediately after venipuncture at 30 minutes (baseline) and 60 minutes (post-intervention) during the oral glucose tolerance test.

07

Study locations

1 site
  • Aydın Adnan Menderes University
    Aydin, Efeler 09010, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jun 2022, 3 months.

Of 144 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 144 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 7, 2022
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944937
Responsible party
Nihal Taskiran (Associate Professor, Aydin Adnan Menderes University) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 7, 2022
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Last update
Nov 18, 2026

Study contacts

Süreyya Bulut
principal investigator · Aydin Adnan Menderes University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion